Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10288MR)

This product GTTS-WQ10288MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10288MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13282MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ9192MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ12058MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ231MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ5942MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ6668MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ13130MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ845MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW